Nadia Soudani
Overview
Explore the profile of Nadia Soudani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
268
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Case J, Sanapala S, Dillen C, Rhodes V, Zmasek C, Chicz T, et al.
Cell Host Microbe
. 2024 Nov;
32(12):2131-2147.e8.
PMID: 39561781
The continued emergence of SARS-CoV-2 variants and the threat of future Sarbecovirus zoonoses have spurred the design of vaccines that can induce broad immunity against multiple coronaviruses. Here, we use...
2.
Soudani N, Bricker T, Darling T, Seehra K, Patel N, Guebre-Xabier M, et al.
J Virol
. 2024 Sep;
98(10):e0052824.
PMID: 39230305
Importance: As SARS-CoV-2 continues to evolve, there is a need to assess the immunogenicity and efficacy of updated vaccines against newly emerging variants in pre-clinical models such as mice and...
3.
Haddara A, Houry Z, Zahreddine N, Atallah M, Boutros C, Tannous J, et al.
J Infect Public Health
. 2024 Aug;
17(9):102521.
PMID: 39173555
Background: Influenza represents a significant global health burden for individuals and society. This study assessed the burden of medically attended influenza at a tertiary medical center in Lebanon to describe...
4.
Darling T, Harastani H, Joshi A, Bricker T, Soudani N, Seehra K, et al.
Sci Adv
. 2024 Jul;
10(31):eadp1290.
PMID: 39083604
COVID-19 vaccines have successfully reduced severe disease and death after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Nonetheless, COVID-19 vaccines are variably effective in preventing transmission and symptomatic SARS-CoV-2...
5.
Vanderheiden A, Hill J, Jiang X, Deppen B, Bamunuarachchi G, Soudani N, et al.
Nat Immunol
. 2024 Jun;
25(7):1158-1171.
PMID: 38902519
Up to 25% of individuals infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibit postacute cognitive sequelae. Although millions of cases of coronavirus disease 2019 (COVID-19)-mediated memory dysfunction are...
6.
Boon J, Soudani N, Bricker T, Darling T, Seehra K, Patel N, et al.
Res Sq
. 2024 Feb;
PMID: 38405749
The continued emergence of SARS-CoV-2 variants necessitates updating COVID-19 vaccines to match circulating strains. The immunogenicity and efficacy of these vaccines must be tested in pre-clinical animal models. In Syrian...
7.
Ying B, Darling T, Desai P, Liang C, Dmitriev I, Soudani N, et al.
Nat Immunol
. 2024 Feb;
25(3):578.
PMID: 38360936
No abstract available.
8.
Ying B, Darling T, Desai P, Liang C, Dmitriev I, Soudani N, et al.
Nat Immunol
. 2024 Feb;
25(3):537-551.
PMID: 38337035
A nasally delivered chimpanzee adenoviral-vectored severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine (ChAd-SARS-CoV-2-S) is currently used in India (iNCOVACC). Here, we update this vaccine by creating ChAd-SARS-CoV-2-BA.5-S, which encodes...
9.
Bricker T, Joshi A, Soudani N, Scheaffer S, Patel N, Guebre-Xabier M, et al.
J Virol
. 2024 Feb;
98(3):e0120623.
PMID: 38305154
Importance: As SARS-CoV-2 continues to evolve, there may be a need to update the vaccines to match the newly emerging variants. Here, we compared the protective efficacy of the updated...
10.
Vanderheiden A, Hill J, Jiang X, Deppen B, Bamunuarachchi G, Soudani N, et al.
Res Sq
. 2023 Oct;
PMID: 37790551
Up to 25% of SARS-CoV-2 patients exhibit post-acute cognitive sequelae. Although millions of cases of COVID-19-mediated memory dysfunction are accumulating worldwide, the underlying mechanisms and how vaccination lowers risk are...